{"created":"2023-06-19T07:25:27.056783+00:00","id":13262,"links":{},"metadata":{"_buckets":{"deposit":"dd0221df-9b7d-402c-9a3d-fc8acfce1019"},"_deposit":{"created_by":32,"id":"13262","owners":[32],"pid":{"revision_id":0,"type":"depid","value":"13262"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013262","sets":["212:267:297"]},"author_link":["19521","19522","19524","19520","19516","19514","19517","19523","19525","19519","19526","19518","19515"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017 Jul","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"1498","bibliographicPageStart":"1492","bibliographicVolumeNumber":"49","bibliographic_titles":[{},{"bibliographic_title":"Transplantation proceedings","bibliographic_titleLang":"en"}]}]},"item_3_text_4":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_text_value":"10.1016/j.transproceed.2017.03.093."}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"BACKGROUND:\nIndividual differences in the pharmacokinetics (PK) of tacrolimus (TAC), an immunosuppressive drug, are reportedly associated with single-nucleotide polymorphisms (SNPs) of cytochrome P450 (CYP) 3A5 and multidrug resistance protein 1 (MDR1). We determined the effect of SNPs in CYP3A5 and MDR1 exons 21 and 26 on TAC PK parameters.\n\nMETHODS:\nThirty-eight Japanese patients who underwent renal transplantation were genotyped for CYP3A5 and exons 21 and 26 of MDR1 with the use of polymerase chain reaction-restriction fragment length polymorphism analysis. TAC concentrations were determined 3 weeks after renal transplantation and PK parameters calculated.\n\nRESULTS:\nThe area under the blood concentration-time curve (AUC) in CYP3A5 expressers was significantly higher than that in CYP3A5 nonexpressers (CYP3A5*3/*3). Patients with the MDR1 exon 21 A allele (G2677A) showed higher dose-adjusted AUC (AUC/D) and lower doses of TAC than those who did not possess that allele. Furthermore, patients with both CYP3A5*3/*3 and MDR1 G2677A showed significantly lower TAC doses and higher dose-adjusted trough levels (C/D) and AUC/D than those without those genotypes. There was no significant association between MDR1 exon 26 polymorphism and the PK of TAC.\n\nCONCLUSIONS:\nPatients with both CYP3A5*3/*3 and MDR1 G2677A had higher blood TAC concentrations than those without those genotypes. Japanese patients should be carefully monitored for consideration of lower TAC doses, because 24% of Japanese patients have double mutations."}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ATP Binding Cassette Transporter, Sub-Family B","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Adult","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Alleles","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Asian Continental Ancestry Group","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cytochrome P-450 CYP3A","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Exons","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Female","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Genotype","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Immunosuppressive Agents","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Kidney Transplantation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Male","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Middle Aged","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Mutation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacogenomic Variants","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Polymerase Chain Reaction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Polymorphism, Single Nucleotide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tacrolimus","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms.","subitem_title_language":"en"}]},"item_type_id":"3","owner":"32","path":["297"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-06-20"},"publish_date":"2017-06-20","publish_status":"0","recid":"13262","relation_version_is_last":true,"title":["Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms."],"weko_creator_id":"32","weko_shared_id":-1},"updated":"2023-06-19T08:57:28.634375+00:00"}